Quinolone Prophylaxis in Transrectal Ultrasound Guided Prostate Biopsy: An Eight-Year Single Center Experience
Table 1
Patient characteristics and clinical presentation of infectious complications.
Group
A (pipemidic acid based prophylaxis)
B (levofloxacin prophylaxis)
P value
Patient characteristics
Patients ()
1313
2381
Age, yrs (mean ± SD)
67.8 ± 10.4
67.7 ± 9.8
0.47
PSAa, ng/mL (mean ± SD)
60.0 ± 432.2
70 ± 437.5
0.5
Sextant biopsy
732 (55.8%)
714 (30.0%)
<0.001
≥12 core biopsy
581 (44.2%)
1667 (70.0%)
<0.001
Outpatient clinic
562 (42.8%)
631 (26.5%)
<0.001
Prostate cancer
342 (26.0%)
759 (31.9%)
<0.001
Chronic inflammation
118 (9.0%)
82 (3.4%)
<0.001
Infectious complications
48 (3.7%)
25 (1.0%)
<0.001
Clinical presentations
Post-op day (mean ± SD)
1.7 ± 1.7
1.2 ± 0.7
0.42
Pyuria (n b, %)
22/38 (57.9%)
16/17 (94.1%)
0.006
Leukocytosis (n c, %)
27/42 (64.3%)
10/19 (52.6%)
0.41
Prolonged hospitalization, days (mean ± SD)
6.4 ± 6.3
5.0 ± 3.4
0.31
Positive urine culture (n d, %)
16/48 (33.3%)
15/25 (60%)
0.046
Positive blood culture (n e, %)
24/48 (50%)
12/25 (48%)
1
The median PSA level is 10.1 and 10.0 ng/mL in group A and group B, respectively.
bn: the number of patients with pyuria/the number of patients receiving urine analyses.
cn: the number of patients with leukocytosis/the number of patients receiving blood tests.
dn: the number of patients with positive urine culture/the number of patients receiving urine culture.
en: the number of patients with positive blood culture/the number of patients receiving blood culture.
